Health Economics and Outcomes Research

Health economics and outcomes research (HEOR) is essential in today’s competitive pharmaceutical landscape for ensuring successful drug development, reimbursement, and market access. At Turacoz, we help biopharma, MedTech, and healthcare stakeholders generate robust economic and real-world evidence to demonstrate the value of therapies to regulatory authorities, payers, healthcare providers, and patients.

By leveraging advanced data analytics, economic modeling, and real-world evidence, we provide comprehensive HEOR solutions to support strategic decision-making at every stage of the drug lifecycle—from early-phase clinical trials to post-market access and beyond.

The Growing Importance of HEOR in Healthcare

As global healthcare systems grapple with escalating costs, intricate reimbursement processes, and stringent regulatory demands, HEOR has become pivotal in healthcare decision-making. Key challenges include:

  • High Drug Development Costs

    Developing a new drug involves substantial financial investment. Recent studies estimate the average out-of-pocket cost per drug at approximately $172.7 million, which can escalate to $515.8 million when accounting for failures and capital costs.

  • Payer Scrutiny

    Approximately one-third of drug launches fail to meet revenue expectations, often due to limited market access and reimbursement challenges.

  • Regulatory and Health Technology

    Agencies such as National Institute for Health and Care Excellence (NICE), Canadian Agency for Drugs and Technologies in Health (CADTH), Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care [IQWiG]), and Institute for Clinical and Economic Review (ICER) mandate comprehensive cost-effectiveness analyses and real-world evidence to support drug approval and reimbursement decisions.

  • Expanding HEOR Services Market

    The global HEOR services market is projected to grow from $1.57 billion in 2024 to $1.76 billion in 2025, representing a compound annual growth rate (CAGR) of 12.4%.

  • Cost-Effectiveness

    This involves assessing the economic value of therapies relative to existing treatments.

  • Budget Impact

    This refers to analyzing the financial implications of introducing new therapies into healthcare systems.

  • Patient Outcomes

    Patient Outcomes

    This includes evaluating real-world treatment benefits and improvements in patients' quality of life.

  • Comparative Effectiveness

    Comparative Effectiveness

    This entails providing evidence on how new treatments perform compared to current standards of care.

Our HEOR Services Include

  • Real-World Evidence (RWE) and Outcomes Research

    This involves generating real-world insights to support regulatory approvals, reimbursement, and clinical adoption. Key methodologies include:

    • Observational studies (prospective and retrospective)
    • Disease registries and patient-reported outcomes (PRO) research
    • Post-marketing surveillance (PMS) and safety studies
    • Epidemiological research and burden of disease studies
    • Comparative effectiveness research
  • Economic Modeling and Market Access Analytics

    This supports pricing and reimbursement strategies with robust health economic models, including:

    • Cost-effectiveness analysis (CEA)
    • Budget impact modeling (BIM)
    • Survival analysis and predictive modeling
    • Markov models and decision tree analysis
    • Multi-criteria decision analysis (MCDA)
  • Systematic Literature Reviews and Evidence Synthesis

    This involves providing scientific evidence to support drug approvals, reimbursement applications, and clinical guidelines through the following approaches:

    • Systematic literature reviews (SLRs)
    • Targeted literature reviews (TLRs)
    • Meta-analysis and network meta-analysis (NMA)
    • Health technology assessments (HTAs) and payer submissions
  • HEOR and Health Technology Assessment (HTA) Submissions

    This involves navigating complex regulatory and reimbursement pathways using tailored HEOR solutions:

    • Dossier preparation for HTA agencies
    • Value proposition and payer engagement strategies
    • Market access consulting and pricing strategy
  • Medical Communications and Scientific Writing

    This involves delivering high-impact scientific publications and evidence-based communications tailored to diverse stakeholders:

    • HEOR-focused manuscripts
    • Value dossiers and health economic reports
    • White papers and thought leadership reports
    • Stakeholder education and training materials

Why Choose Turacoz?

  • Multidisciplinary Expertise

    Turacoz has a multidisciplinary team of PhDs, biostatisticians, health economists, and medical writers specializing in HEOR.

  • Industry-Leading RWE Solutions

    Industry-Leading RWE Solutions

    Turacoz has proven its expertise in            real-world data analysis, observational studies, and economic modeling.

  • Global Experience, Local Impact

    Global Experience, Local Impact

    Turacoz operates in India, Singapore, and the Netherlands, while supporting global regulatory submissions.

  • 20+ Therapeutic Areas Covered

    Turacoz delivers end-to-end support in oncology, cardiology, neurology, infectious diseases, rare diseases, and more—driving impactful solutions across diverse therapeutic landscapes.

  • Proven Track Record

    Proven Track Record

    Turacoz is recognized for excellence and has empowered clients worldwide to achieve success with clarity and precision.

partner with us

Partner with Turacoz to bring science to life through strategic and evidence-based communication.

Partner with Us